BCX-1777, Forodesine HCl

Phase II Multi-Center, Open-Label, Repeat-Dose Study of BCX-1777 (Forodesine Hydrochloride) Infusion in Patients with Advanced T-cell Leukemia with an Option of Long Term BCX-1777 Use


Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients with Refractory Cutaneous T-Cell Lymphoma

Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-Cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride

BCX-4208

Phase I Randomized, Double-Blind, Placebo-Controlled, Multiple, Oral Dose Study of BCX-4208 in Healthy Volunteers